Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) Trial: results of a German substudy

References

• Coates AS, Keshaviah A, Thurlimann B, . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol 2007;25: 486–92
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF, . Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559–70
   PubMed Web of Science ®Google Scholar
• Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45–53
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319–29
   PubMed Web of Science ®Google Scholar
• Chlebowski R, Cuzick J, Amakye D, . Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast 2009;18(Suppl 2):S1–11
   PubMedGoogle Scholar
• Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172–86
   PubMed Web of Science ®Google Scholar
• Brodie AH, Jelovac D, Long B. The intratumoral aromatase model: studies with aromatase inhibitors and antiestrogens. J Steroid Biochem Mol Biol 2003;86:283–8
   PubMed Web of Science ®Google Scholar
• Early breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717
   PubMed Web of Science ®Google Scholar
• Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocrine-Related Cancer 2008;15:73–90
   PubMed Web of Science ®Google Scholar
• Miller WR, Bartlett J, Brodie AM, . Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008;13: 829–37
   PubMed Web of Science ®Google Scholar
• van de Velde CJH, Rea D, Seynaeve C, . Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011;377:321–31
   PubMed Web of Science ®Google Scholar
• Coombes RC, Hall E, Gibson LJ, . A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081–92
   PubMed Web of Science ®Google Scholar
• Evans TR, Di SE, Ornati G, . Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Res 1992;52:5933–9
   PubMed Web of Science ®Google Scholar
• Johannessen DC, Engan T, Di SE, . Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101–8
   PubMed Web of Science ®Google Scholar
• Goss PE, Hadji P, Subar M, Abreu P, Thomsen T, Banke-Bochita J. Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women. Breast Cancer Res 2007;9:R52
   PubMed Web of Science ®Google Scholar
• Hadji P, Ziller M, Kieback DG, . Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised sub-study. Ann Oncol 2009;20:203–7
   Google Scholar
• Hadji P, Ziller M, Kieback DG, . The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 2009;18:159–64
   PubMed Web of Science ®Google Scholar
• Mitwally MF, Casper RF, Diamond MP. Oestrogen-selective modulation of FSH and LH secretion by pituitary gland. Br J Cancer 2005;92:416–17
   PubMed Web of Science ®Google Scholar
• Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215–23
   PubMed Web of Science ®Google Scholar
• Rossi E, Morabito A, Di RF, . Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 2009;27:3192–7
   PubMed Web of Science ®Google Scholar
• van Londen GJ, Perera S, Vujevich K, . The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer. Breast Cancer Res Treat 2011;125:441–6
   PubMed Web of Science ®Google Scholar
• Rothman MS, Carlson NE, Xu M, . Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids 2011;76:177–82
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007;16:1713–19
   PubMed Web of Science ®Google Scholar
• Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab 1995; 80:1429–30
   PubMed Web of Science ®Google Scholar
• Brand JS, van der Schouw YT. Testosterone, SHBG and cardiovascular health in postmenopausal women. Int J Impot Res 2010;22:91–104
   PubMed Web of Science ®Google Scholar
• Patel SM, Ratcliffe SJ, Reilly MP, . Higher serum testosterone concentration in older women is associated with insulin resistance, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2009;94:4776–84
   PubMed Web of Science ®Google Scholar
• Ding EL, Song Y, Manson JE, . Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009;361:1152–63
   PubMed Web of Science ®Google Scholar
• Ewer MS, Gluck S. A woman’s heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 2009;115: 1813–26
   PubMed Web of Science ®Google Scholar